GLP-1 weight loss claims on TikTok: separating fact from hype

What did @clareedgar6 actually say?

After stopping GLP-1 medication for five weeks due to price increases, @clareedgar6 switched from tirzepatide (Mounjaro) to semaglutide (Wegovy), starting at 1mg. She describes it as "like injecting water" with zero appetite suppression, no food noise reduction, and continued weight gain. She spent £140 on Wegovy, saw no results, and has since returned to tirzepatide, sourcing it from a service called Checkup and also purchasing through Juniper with a discount code.

She also describes injecting what she frames as a 7.5mg tirzepatide equivalent dose after a five-week break, having been on 10mg previously, and says she expected severe side effects but experienced none.

Does the science back this up?

There is legitimate clinical evidence that tirzepatide produces greater weight loss than semaglutide, so her experience is not scientifically implausible. But calling Wegovy "rubbish" for everyone oversimplifies a more complicated picture.

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean weight loss of around 20.9% of body weight. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced approximately 14.9% mean weight loss. Head-to-head data from the SURMOUNT-5 trial (2024) confirmed tirzepatide outperformed semaglutide in direct comparison, with roughly 47% more weight loss at the highest doses. So the gap is real and documented.

However, "done nothing" is a strong claim. Individual response varies considerably. Some patients do respond strongly to semaglutide, particularly those who have not previously been on tirzepatide. The issue she may be experiencing is tolerance or desensitisation from prior tirzepatide exposure, not a universal failure of semaglutide.

What did they get wrong (or right)?

She got the general direction right: tirzepatide does tend to outperform semaglutide in clinical trials. She deserves credit for being honest about weight regain during her five-week break, which is consistent with what studies show about GLP-1 discontinuation.

Where she goes wrong is in her dose equivalency framing. She says 1mg Wegovy is "equivalent to 7.5" of Mounjaro. This is not an established clinical conversion. Semaglutide and tirzepatide work through different mechanisms. Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide is a GLP-1 receptor agonist only. You cannot map one dose onto the other as equivalents. That framing is misleading and should not be repeated as fact.

She also does not mention that starting any GLP-1 after a five-week gap typically requires re-titration from a lower dose, meaning 1mg semaglutide may have been an appropriate starting point, not a direct comparison to her previous 10mg tirzepatide.

What should you actually know?

If you are considering switching between GLP-1 medications, there are a few things worth knowing before you spend £140 based on TikTok feedback.

• Tirzepatide and semaglutide are not interchangeable by dose. They bind to different receptors and have different mechanisms. There is no validated dose conversion chart between them.
• Weight regain after stopping GLP-1 treatment is well-documented. The STEP 4 trial (Rubino et al., 2021, JAMA) showed participants regained about two-thirds of lost weight within a year of stopping semaglutide. A five-week gap is enough to see meaningful regain, as this creator experienced.
• Individual response to semaglutide versus tirzepatide varies. The population averages from SURMOUNT-5 do not predict your personal outcome. Some people respond well to semaglutide; others respond better to tirzepatide.
• Sourcing GLP-1 medications from discount codes and multiple platforms raises questions about supply chain, cold storage, and whether you are receiving genuine licensed product. This is not a minor concern.
• Any switch between GLP-1 medications should involve a prescribing clinician, not a TikTok comment section.

The bottom line

@clareedgar6 is describing a real phenomenon that has some clinical backing: tirzepatide does produce greater average weight loss than semaglutide in trials. Her personal experience, while frustrating, is plausible. But her claim that Wegovy is universally ineffective, combined with inaccurate dose equivalency framing, is the kind of content that nudges viewers toward medication decisions without the full picture. The science says tirzepatide tends to win on average. It does not say semaglutide is water.